| Similar Articles |
 |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.  |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?  |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.  |
The Motley Fool July 6, 2007 Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.  |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.  |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.  |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.  |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.  |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.  |
The Motley Fool April 4, 2007 Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.  |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.  |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.  |
The Motley Fool March 28, 2005 Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?  |
The Motley Fool March 24, 2008 Timothy M. Otte |
Expecting More From Walgreen The drugstore giant has managed to beat analyst estimates two quarters in a row, but earnings are lagging sales growth, and growth is slowing too.  |
The Motley Fool September 28, 2007 Timothy M. Otte |
Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth.  |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.  |
The Motley Fool September 24, 2004 Seth Jayson |
Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.  |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.  |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.  |
The Motley Fool October 2, 2007 Lawrence A. Rothman |
Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.  |
The Motley Fool October 5, 2007 Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.  |
The Motley Fool September 30, 2009 Chris Jones |
A Tough Pill to Swallow Health-care reform's shadow of uncertainty looms over Walgreen's productive fiscal year.  |
The Motley Fool March 26, 2007 Ryan Fuhrmann |
Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.  |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...  |
The Motley Fool June 21, 2004 Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.  |
The Motley Fool June 23, 2006 Rich Smith |
Foolish Forecast: Walgreen The retail pharmacy reports its fiscal third-quarter 2006 earnings on Monday. Investors -- buy, sell or waffle?  |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.  |
The Motley Fool March 23, 2011 Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.  |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.  |
The Motley Fool September 20, 2006 Alyce Lomax |
CVS, Up to the Minute The drugstore company's clinic acquisition shows it's aggressively chasing current trends. This is good news for investors.  |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?  |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.  |
The Motley Fool March 6, 2008 Timothy M. Otte |
Longs Drugs Has a Nice Niche West Coast regional drugstore chain scores solid fourth quarter.  |
The Motley Fool March 26, 2010 Cathy Applefeld Olson |
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup.  |
The Motley Fool April 8, 2004 Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.  |
The Motley Fool January 3, 2012 Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts.  |
The Motley Fool April 26, 2006 Brian Gorman |
Walgreen's Clinics In-store clinics could be more trouble than they're worth. Investors, take note.  |
The Motley Fool May 8, 2007 Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.  |
The Motley Fool March 26, 2007 Ryan Fuhrmann |
A Healthy Shade of Walgreen: Fool by Numbers The drugstore chain released second-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...  |
The Motley Fool September 27, 2007 Anders Bylund |
Rite Aid's Strong Prescription: Fool by Numbers The fast facts on convenience store and pharmacy operator Rite Aid's second-quarter 2008 reports. Despite peaked sales, the company's recent remedy of adding new brand-name stores to its portfolio didn't seem to trickle to the bottom line.  |
The Motley Fool September 22, 2005 Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.  |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.  |
The Motley Fool August 16, 2007 Lawrence Rothman |
Longs' Prescription for Success Longs Drug Stores may be small, but it excels in its regional niche. Operating primarily on the West Coast, second-quarter results show a company with lots of room for growth.  |
The Motley Fool October 6, 2004 Steven Mallas |
Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage.  |
The Motley Fool October 7, 2010 |
DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio.  |
The Motley Fool August 1, 2007 Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.  |
The Motley Fool January 9, 2006 Rick Aristotle Munarriz |
3 Stocks That Blew the Market Away Beat the market and the world will beat a path to your door: Constellation Brands... Monsanto... Walgreen...  |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.  |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.  |
The Motley Fool September 21, 2006 Vitaliy Katsenelson |
Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.  |